JZJie Zhu

Jie Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jie Zhu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Jingyi Hou

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Orthopedic, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China

    1 shared publication
  • Menglei Yu

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Emergency Department, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China

    1 shared publication
  • Minghui Zheng

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Clinical Laboratory, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China

    1 shared publication
  • Yamuhanmode Alike

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Emergency Department, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China

    1 shared publication
  • Yang Rui

    Sun Yat-Sen University, Guangzhou, PR China, Guangzhou, China

    1 shared publication
  • Yi Cao

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Emergency Department, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China

    1 shared publication

Latest Publications

  • Open Access

    IL-21 gene rs6822844 polymorphism and rheumatoid arthritis susceptibility

    by Menglei Yu, Jingyi Hou, Minghui Zheng, Yi Cao, Yamuhanmode Alike, Yang Rui, Yuanyuan Mi, Jie Zhu

    Interleukin-21 (IL-21) is a cytokine that plays a crucial role in pathogenesis and activity of the rheumatoid arthritis (RA). Meanwhile, genetic polymorphisms in the IL-21 gene may alter its expression. Previous studies have reported conflicting results assessing the association between the IL-21 rs6822844 G/T polymorphism and RA risk. Thus, it's necessary to perform a meta-analysis to definite above relationship. PubMed database was searched for all papers published until Oct 20, 2019. Nine case-control studies with 9998 cases and 10742 controls were retrieved based on the search criteria at last. Odds ratio (95% confidence interval) was used to calculate the strength of this association. Publication bias was detected using both Begg and Egger tests. Overall, the IL-21 rs6822844 G/T polymorphism was found to be significantly associated with decreased RA risk (eg: T-allele vs. G-allele: OR= 0.81, 95% CI= 0.72-0.91, P < 0.001). In addition, decreased RA risk was also detected both in Asians (eg: TT+TG vs. GG: OR = 0.42, 95% CI = 0.31-0.56, P< 0.001) and Caucasians (eg: TT+TG vs. GG: OR = 0.85, 95% CI = 0.80-0.91, P< 0.001). A similar trend in association was found in the source of the control and genotype method subgroups. Furthermore, subgroup analysis of rheumatoid factor status, revealed a protective relationship between the IL-21 rs6822844 G/T polymorphism and RF+/RF- RA risk. A similar relationship was noted in the anti-citrullinated protein antibody status subgroup. The results of this study suggest that the IL-21 rs6822844 G/T polymorphism was significantly associated with decreased RA susceptibility.